Alnylam Pharma (ALNY) Announces Positive Topline 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
CEO Departure Likely to Pressure Alnylam (ALNY) Stock, M&A Possibility Will Likely Fade - Analyst
October 28, 2021 8:41 AM EDTEarlier today, alongside its Q3 report, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) announced the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, at... More
Alnylam Pharma (ALNY) Announces Planned Retirement of CEO John Maraganore
October 28, 2021 7:56 AM EDTAlnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the planned CEO transition of John Maraganore, Ph.D., to Yvonne Greenstreet, MBChB, at year-end 2021. Dr. Maraganore joined Alnylam in 2002 as the companys founding CEO and has led the companys advancement of RNAi therapeutics as a whole new class of... More
